IP Library Granted Patent US 11,078,505
Granted Patent B2
US 11,078,505 · App. 16/807,977 · Granted Aug 3, 2021

Transaminase biocatalysts

Inventors: Christopher K. Savile (Santa Clara, CA); Emily Mundorff (Garden City, NY); Jeffrey C. Moore (Westfield, NJ); Paul N. Devine (Tinton Falls, NJ); Jacob M. Janey (New York, NY)
Assignee: Codexis, Inc.
C12P17/182C12N9/1096C12N15/52C12P13/001C12Y206/01018C12N15/62Y02P20/52
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,078,505
App. No.
16/807,977
Granted
Aug 3, 2021
Kind
B2
Abstract

The present disclosure relates to polypeptides having transaminase activity, polynucleotides encoding the polypeptides, and methods of using the polypeptides.

Claims (5)

1. A recombinant transaminase polypeptide comprising an amino acid at least 95% sequence identical to SEQ ID NO: 2 having transaminase activity, wherein the amino acid sequence of the recombinant transaminase polypeptide comprises residue difference as compared to SEQ ID NO: 2 at residue positions X62, X69 and X169.

2. The recombinant transaminase polypeptide of claim 1 , wherein said recombinant transaminase polypeptide is capable of converting 4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-one (“ketoamide substrate”) to (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine (“product”) under a defined reaction condition in the presence of an amino group donor isopropylamine to levels of the product detectable by HPLC-UV at 210 nm, where the reaction condition comprises about 2 g/L ketoamide substrate, about 0.5 M isopropylamine, about 22° C., about pH 7.5, about 5% DMSO, about 100 μM pyridoxal phosphate, and about 20 mg/mL of transaminase polypeptide.

3. The recombinant transaminase polypeptide of claim 1 , wherein said recombinant transaminase polypeptide is capable of converting the ketoamide substrate to the product with an activity that is equal to or greater than the activity of the polypeptide of SEQ ID NO: 4 under the defined reaction condition.

4. The recombinant transaminase polypeptide of claim 1 , wherein said recombinant transaminase polypeptide is capable of converting the ketoamide substrate to product in at least 90% enantiomeric excess.

5. The recombinant transaminase polypeptide of claim 1 , wherein said recombinant transaminase polypeptide is capable of converting the ketoamide substrate to product in at least 99% enantiomeric excess.

Assignments (1)
SECURITY INTEREST Recorded Feb 15, 2024
From: CODEXIS, INC.
To: INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT
Reel/Frame 066600/0650 →
Continuity (10)
Continuation 16195227 · Nov 19, 2018
Continuation 15915437 · Mar 8, 2018
Division 15376837 · Dec 13, 2016
Continuation 15140809 · Apr 28, 2016
Division 14818885 · Aug 5, 2015
Division 14518143 · Oct 20, 2014
Division 13604323 · Sep 5, 2012
Continuation 12714397 · Feb 26, 2010
Provisional Application 61155902 · Feb 26, 2009
Related Publication 20200199636A1 · Jun 25, 2020